AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Inspira Technologies has secured a $22.5 million purchase order for its FDA-cleared ART100 system, marking its transition to full-scale revenue generation. The deal, with payment scheduled for 2025, validates the company's market potential and is part of a broader commercial strategy, including strategic partnerships and further agreements with healthcare companies. This transition from R&D to revenue focus enables manufacturing scale-up and infrastructure development.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet